Mixpanel vs Google Analytics for Healthcare Apps

Mixpanel and Google Analytics can both answer questions about user behavior, but they are not interchangeable in a HIPAA-regulated product. Google Analytics does not offer a Business Associate Agreement and instructs regulated entities not to expose PHI to the service. Mixpanel says qualifying Enterprise customers can enter into a BAA, and its current DPA requires that separate agreement before PHI reaches the application service.

That creates a practical architecture decision. Google Analytics can be considered only for surfaces the organization has classified as outside its HIPAA-covered data flow and kept free of PHI and Google-prohibited identifying data. Mixpanel can be considered for in-product analytics only after the exact account, features, region, data flow, and executed documents are approved.

The BAA position is different

Google states that it does not offer BAAs for Google Analytics and makes no representation that the service satisfies HIPAA requirements. A Google Cloud BAA is a different contract for listed Google Cloud products. Google Cloud tells customers not to use products outside that covered list with PHI; accepting that BAA does not make Google Analytics a covered service.

Mixpanel's current terms define several categories of prohibited information, including health data and sensitive data, and separately allow PHI only as permitted by an executed HIPAA BAA. Its DPA also says sensitive personal information is not expected unless the agreement specifically provides for it. Treat the signed BAA, order form, DPA, terms, and feature-specific terms as one scope package and resolve any ambiguity in writing before collection.

A provider contract makes a data flow contractually possible. Implementation safety still depends on configuration, access, event design, retention, deletion, integrations, and ongoing inspection. A BAA does not approve every feature or turn unnecessary data into necessary data.

Which problem does each tool solve?

Public does not always mean free of PHI

It is tempting to install Google Analytics on every unauthenticated page and remove it after login. That is a useful starting boundary, but it is not the complete test. HHS's tracking bulletin says the HIPAA Rules apply when tracking data includes PHI, and it treats authenticated pages and regulated-entity mobile apps as high-risk contexts.

The HHS page also records a 2024 court order vacating part of the bulletin: an IP address combined only with a visit to an unauthenticated public page about a condition or provider is not, by itself, sufficient under the vacated interpretation. That does not make every public page safe. Login and registration fields, an existing care relationship, appointment intent, precise parameters, or other context can change the data flow. Google independently tells regulated entities to use Analytics only on pages that are not HIPAA-covered.

Engineering must control fields Analytics collects automatically or accepts through configuration. Page paths, titles, query strings, internal search terms, User-ID, custom dimensions, campaign values, cookies, app instance IDs, and advertising identifiers can reveal identity or sensitive context. Google's best-effort email and query-parameter redaction is defense in depth, not permission to send those values.

A BAA makes a reviewed data flow possible, not automatically safe

Mixpanel is designed around named events, properties, user profiles, funnels, cohorts, and retention. That fits questions such as where users abandon onboarding, whether a feature improves completion, or which release changed behavior.

The same flexibility can create an uncontrolled clinical data warehouse. Mixpanel's current DPA lists default collection that can include location, browser, device, and current URL. Event properties are easy to add, profiles accumulate over time, and integrations can copy data elsewhere. Start with the product question, then design the smallest schema that answers it.

Even under a BAA, avoid clinical free text and direct identifiers when they do not serve the analysis. Restrict who can create properties, export data, connect destinations, or view sensitive projects. Review session replay, warehouse connectors, AI features, experiments, feature flags, messaging, and every third-party integration against the current BAA and supplemental terms before enabling them.

Pseudonymous IDs are useful controls, not de-identification

For persistent product analysis, use a random analytics subject ID that is separate from email, phone, medical record number, account number, or an identity-provider subject. Keep the lookup in the approved application boundary. Reset the SDK on logout and test shared-device and account-switching behavior so one person's events do not merge into another profile.

A stable token can still be identifying or PHI when it is linkable to a person or combined with healthcare context. Do not call a payload anonymous or de-identified merely because it replaces a name with a hash. HHS's Safe Harbor method has specific identifier-removal and knowledge requirements; analytics minimization is not a shortcut to that determination.

Consent and HIPAA permission are separate checks. A cookie banner or Consent Mode may be required for privacy rules and user choice, but it does not create a BAA, authorize a PHI disclosure, or make a prohibited payload acceptable. In Google Consent Mode, denied-consent pings and modeled reporting can still occur, so test the actual network behavior rather than assuming the banner blocks collection.

Separate measurement zones

Separate keys, projects, domains, tag-manager containers, environments, and access roles make the boundary easier to enforce. For Mixpanel, select and contract the required data location before creating production projects. For Google Analytics, regional collection and regional signal controls do not mean all Analytics processing is confined to a customer-selected region.

Retention, deletion, and export are architecture decisions

Set the shortest useful retention before launch and document what the setting actually covers. Google Analytics standard properties offer two- or fourteen-month user and event retention, while its documentation says standard aggregated reports are not affected by that control. Data-deletion requests and the User Deletion API exist, but linked roll-up properties and modeled data can require additional handling.

Mixpanel provides end-user export and deletion tooling and supports configurable retention, while its current DPA describes deletion on request or within ninety days after termination. Confirm how the purchased configuration handles events, profiles, merged identities, backups, project deletion, and termination. Test deletion with the same analytics subject IDs used at ingestion.

An export is another copy, not an escape from governance. Inventory CSV downloads, APIs, warehouse pipelines, dashboards, reverse ETL, messaging, advertising, support, and experiment destinations. Apply access, retention, deletion, audit, and incident rules to each destination independently.

Measure workflow state, not the patient's story

A useful event describes what the product did at a level that supports a decision. For an appointment flow, an event such as booking_step_completed can carry an allowlisted step name, outcome, channel, application release, and broad user cohort. It usually does not need the patient's name, email, medical record number, diagnosis, clinician, appointment time, free-text reason, or raw URL.

Even the preferred event needs classification in its real context. Keep the schema in version control, reject unknown event names and properties at the collection boundary, cap string lengths, disallow free text, and inspect captured payloads before and after every SDK or tag-manager change.

A safer analytics baseline

1. Classify every website and application surface before adding a tracking SDK or tag.
2. Document whether the vendor will create, receive, maintain, or transmit PHI.
3. Execute the applicable BAA before allowing PHI into a covered analytics service.
4. Confirm the account, plan, BAA, DPA, order form, region, and every enabled feature are in scope.
5. Define an event and property allowlist instead of permitting arbitrary payloads or autocapture.
6. Block free text, raw URLs, query strings, form values, clinical values, direct identifiers, and unapproved default properties.
7. Separate public-site analytics from authenticated product analytics.
8. Connect consent and deletion workflows to the SDK, identity map, vendor APIs, exports, and downstream copies.
9. Review destination integrations, exports, replay, experiments, feature flags, warehouse connectors, and AI features independently.
10. Inspect real network payloads in production-like testing and monitor for schema drift.

My practical recommendation

Use Google Analytics only where the organization has determined that the surface is outside the HIPAA-covered data flow and verified that the implementation sends neither PHI nor Google-prohibited identifying or sensitive data. Keep it away from authenticated healthcare workflows by default, and do not rely on a Google Cloud BAA, a consent banner, or redaction to change that product boundary.

Evaluate Mixpanel when the team needs product analytics inside a healthcare application and can support Enterprise procurement, exact BAA and feature review, access control, event governance, deletion testing, and integration review. The goal is not to send PHI because a contract may permit it. The goal is to collect the minimum data required to improve the product and to prove that the controls continue to work.

Continue the implementation

Official references reviewed 2 August 2026: Mixpanel HIPAA program, Mixpanel terms, Mixpanel DPA, Mixpanel security and deletion details, Google Analytics and HIPAA, Google guidance for avoiding PII, Google Analytics retention, Google consent management, Google Cloud HIPAA scope, and HHS tracking guidance and court notice.